

Drugs and Devices Division

Drug Submission Status

Report for July 2019

Complete Streamlined Multiple-Source

Submissions for Off-Formulary Interchangeability

The Ministry of Health and Long-Term Care has received complete submissions for the following streamlined multiple-source drug products for Off-Formulary Interchangeability (OFI) designation. Subject to confirmation of Drug Identification Numbers (DIN) and prices by the manufacturers, as well as review and approval by the Executive Officer, these products may be designated as OFI drugs in a future Formulary update. Final OFI designation status will be communicated when the Formulary update is published on the Ministry website and via a DDD Notice.

Manufacturer	Product	Reference Product	Generic Name	Strength	Dosage Form	DIN
Fresenius Kabi Canada Ltd.	Pamidronate Disodium for Injection	Aredia	pamidronate disodium	3 mg/mL	IV solution	02246597
Fresenius Kabi Canada Ltd.	Pamidronate Disodium for Injection	Aredia	pamidronate disodium	6 mg/mL	IV solution	02246598
Fresenius Kabi Canada Ltd.	Pamidronate Disodium for Injection	Aredia	pamidronate disodium	9 mg/mL	IV solution	02246599
Sandoz Canada Inc.	Sandoz Gefitinib	Iressa	gefitinib	250 mg	tablet	02487748